Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill takes on tough blood cancers in early human trial

NCT ID NCT06980116

Recruiting now Disease control Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Dec 26, 2025 · Last updated May 08, 2026 · Updated 15 times

Summary

This early-stage study tests an experimental oral drug, EXS73565, in about 50 adults with relapsed or treatment-resistant B-cell cancers (like certain lymphomas and leukemias). The main goal is to check safety and find the right dose, while also looking for early signs that the drug can shrink or control tumors. Participants must have tried standard treatments first.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Fundación Jiménez Diaz

    RECRUITING

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro

    RECRUITING

    Madrid, Spain

  • St James's University Hospital

    RECRUITING

    Leeds, United Kingdom

  • University Hospitals Plymouth NHS Trust

    RECRUITING

    Plymouth, United Kingdom

Conditions

Explore the condition pages connected to this study.

RELAPSED OR REFRACTORY B-CELL MALIGNANCIES